JUBILANT LIFESCIENCES

May 11, 2016

**BSE Limited**
Corporate Service Department
1st Floor, New Trading Ring
Rotunda Building, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001

**The National Stock Exchange of India Ltd.**
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051

Dear Sirs,

We enclose a copy of the Announcement being issued by the Company.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

Encl.: as above



**Jubilant Life Sciences Limited**
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel:+91 120 4361000
Fax:+91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624

**Jubilant Life Sciences Ltd.**
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubl.com

# Jubilant and Cyclopharm mutually agree to terminate term sheet for Technegas licensing agreement

***Noida (UP), India, Wednesday, May 11, 2016***

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences company, today announced that one of its wholly-owned subsidiaries, Jubilant DraxImage Inc ("JDI") and Cyclopharm Ltd (ASX:CYC) ("CYC") have mutually terminated their previously announced term sheet for exclusive commercial rights of Technegas in the US market. Both parties have agreed to discuss potential commercial opportunities once CYC obtains USFDA approval for Technegas.

**About Jubilant Life Sciences**

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 12 world-class manufacturing facilities in India, US and Canada and a team of about 6,100 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

## For more information please contact:

***For Investors***

Ravi Agrawal / Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1002 / 1021
E-mail: ravi_agrawal@jubl.com
anupam_jain@jubl.com

Siddharth Rangnekar / Karl Kolah
Citigate Dewe Rogerson
Ph: +91 22 6645 1209 / 1220
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

***For Media***

Sudhakar Safaya
Jubilant Life Sciences Limited
Ph: +91-120 436 1034
E-mail: sudhakar_safaya@jubl.com

Kanika Mittal
Perfect Relations
Ph: +91 9899574833
E-mail: kmittal@perfectrelations.com

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*